*March 2022*
Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn’t Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.